Search Results for: Neuralstem

Interview with Neuralstem CEO Richard Garr

I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting?  Garr: Neuralstem is moving on all cylinders these days on …

Interview with Neuralstem CEO Richard Garr Read More »

Interview with Ted Harada Part 2: Right To Try, Neuralstem, and How He’s Doing

Harada-Family-e1479769086296

This is Part 2 of my interview with ALS and stem cell advocate, Ted Harada. You can read Part 1 of my talk with Ted on where things stand today with ALS, the FDA, and the Ice Bucket Challenge. What’s your opinion of the “Right To Try” law in Colorado and the concept more generally? …

Interview with Ted Harada Part 2: Right To Try, Neuralstem, and How He’s Doing Read More »

Neuralstem flirting with noncompliance via Right To Try Law?

Is Neuralstem flirting with noncompliance via a Right To Try Law in Colorado? Colorado is an independent-minded state. For example, it is one of only a few states including Washington State with legalized marijuana use. More recently, Colorado passed a new law supported by the ultra-conservative Goldwater Institute, the so-called Right To Try Law. This law …

Neuralstem flirting with noncompliance via Right To Try Law? Read More »

Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer

What’s going on these days with biotech companies working on stem cell-based products? Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they apply for CIRM funding and (2) if so, how did the review process …

Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell therapy arena. Today …

24 cell therapy & stem cell stocks I’m following Read More »

Critical new piece on MD Stem Cells purported Right To Try program: let’s dig into it

Steven-Levy-Jeffrey-Weiss

I’ve been concerned about a stem cell group called MD Stem Cells for many years. Now it comes under more scrutiny from a new must-read piece by Donna Young over at S&P Global. Young’s article reports a puzzling, purported right-to-try (RTT) program that MD Stem Cells appears to working on with Richard Garr. Note that …

Critical new piece on MD Stem Cells purported Right To Try program: let’s dig into it Read More »

Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope

NSRichard08-headshot

A new right-to-try company called Beacon of Hope is stirring some intense discussion. State and federal right-to-try laws could potentially change the fabric of how many investigational studies are conducted. That may happen through firms like Beacon of Hope. However, we don’t know much about the firm. I’m hoping to help change that. Today’s post …

Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope Read More »

Stem Cell Person of the Year 2016: Patient Advocate Ted Harada

Stem-cell-ethics-meeting-e1479769073498

Patient advocate Ted Harada is the recipient of this year’s Stem Cell Person of the Year Award. Congrats also to the runner-up, HD patient advocate Judy Roberson. The three of us together are pictured at left. You can read about the 20 nominees here and see the vote results that picked the 10 finalists here. …

Stem Cell Person of the Year 2016: Patient Advocate Ted Harada Read More »

Tribute to Ted Harada, pioneering stem cell trial participant and ALS advocate

Harada-Family-e1479769086296

It takes a great deal of courage to participate in a clinical trial, patients who make that choice are heroes in my book and one such hero with stem cells was Ted Harada who had ALS. Sadly, Ted passed away from a brain tumor called glioblastoma last month. When enrolling in a trial, you just never …

Tribute to Ted Harada, pioneering stem cell trial participant and ALS advocate Read More »

End of line for StemCells Inc., pioneering & controversial stem cell biotech

stemcellsinc-logo

A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for …

End of line for StemCells Inc., pioneering & controversial stem cell biotech Read More »